Filing Flows › Companies › Ultragenyx Pharmaceutical › Timeline
Ultragenyx Pharmaceutical stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−50.2% to $15.43
Ultragenyx Pharmaceutical (RARE) stock fell 50% over the last 252 sessions, to $15.43. On the way it reported 4 quarters, its insiders filed 9 open-market trades and 2 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 3, 2026 | Earnings | Earnings: missed the EPS estimate by -54.4% | +2.0% (+1.7% vs SPY) | — | — |
| Oct 14, 2026 | 8-K | Material definitive agreement | −0.1% (+1.0% vs SPY) | +7.1% (+8.3% vs SPY) | — |
| Oct 7, 2026 | 8-K | Material definitive agreement | +2.9% (+3.2% vs SPY) | +3.1% (+3.3% vs SPY) | +17.1% (+18.7% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: beat the EPS estimate by 9.7% | +3.1% (+1.3% vs SPY) | +6.9% (+4.9% vs SPY) | +3.1% (+2.6% vs SPY) |
| Aug 3, 2026 | Form 144 | Form 144: Howard Horn plans to sell $117K | +0.4% (−1.0% vs SPY) | +3.9% (+0.5% vs SPY) | +1.2% (−1.4% vs SPY) |
| Jul 1, 2026 | Form 144 | Form 144: Howard Horn plans to sell $156K | −3.1% (−2.9% vs SPY) | +3.8% (+3.9% vs SPY) | −24.9% (−24.2% vs SPY) |
| Jun 15, 2026 | Insider sale | Sanders Corazon (Corsee) D. sold $50K | +4.1% (+2.4% vs SPY) | +17.6% (+17.0% vs SPY) | +26.4% (+24.4% vs SPY) |
| May 18, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.3% (−3.2% vs SPY) | −6.7% (−7.5% vs SPY) | −0.6% (−2.1% vs SPY) |
| May 5, 2026 | Earnings | Earnings: missed the EPS estimate by -5.7% | +0.8% (0.0% vs SPY) | +5.8% (+2.9% vs SPY) | −10.2% (−15.1% vs SPY) |
| Mar 10, 2026 | Insider sale | Parschauer Karah Herdman sold $80K | +1.0% (+1.2% vs SPY) | −3.6% (−2.2% vs SPY) | +2.3% (+2.4% vs SPY) |
| Mar 6, 2026 | Insider sale | Parschauer Karah Herdman sold $129K | −1.0% (+0.3% vs SPY) | +1.1% (+3.4% vs SPY) | +6.3% (+9.4% vs SPY) |
| Mar 2, 2026 | Insider sale | Pinion John Richard sold $229K | −1.6% (−1.6% vs SPY) | −9.6% (−7.6% vs SPY) | −19.2% (−11.3% vs SPY) |
| Mar 2, 2026 | Insider sale | Parschauer Karah Herdman sold $185K | −1.6% (−1.6% vs SPY) | −9.6% (−7.6% vs SPY) | −19.2% (−11.3% vs SPY) |
| Mar 2, 2026 | Insider sale | Kakkis Emil D sold $1.2M | −1.6% (−1.6% vs SPY) | −9.6% (−7.6% vs SPY) | −19.2% (−11.3% vs SPY) |
| Mar 2, 2026 | Insider sale | Huizenga Theodore Alan sold $37K | −1.6% (−1.6% vs SPY) | −9.6% (−7.6% vs SPY) | −19.2% (−11.3% vs SPY) |
| Mar 2, 2026 | Insider sale | Harris Erik sold $240K | −1.6% (−1.6% vs SPY) | −9.6% (−7.6% vs SPY) | −19.2% (−11.3% vs SPY) |
| Mar 2, 2026 | Insider sale | Crombez Eric sold $160K | −1.6% (−1.6% vs SPY) | −9.6% (−7.6% vs SPY) | −19.2% (−11.3% vs SPY) |
| Feb 12, 2026 | 8-K | Exit or disposal costs | −13.6% (−13.6% vs SPY) | −3.4% (−4.6% vs SPY) | −7.4% (−5.6% vs SPY) |
| Feb 12, 2026 | Earnings | Earnings: missed the EPS estimate by -10.1% | −1.6% (0.0% vs SPY) | −9.0% (−7.9% vs SPY) | −11.2% (−6.8% vs SPY) |
Insiders’ record here
In the year on the chart, Ultragenyx Pharmaceutical's insiders reported 0 open-market buys ($0) and 9 sales ($2.4M). Of the 9 old enough to score, 9 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −11.2%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 2.05 Exit or disposal costs | 954 | −0.2% | 47% | +0.5% | ±2.4% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Ultragenyx Pharmaceutical: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.